Jensen Global Quality Growth

A consistent, sustainable investment process is vital to weathering all economic climates. The strength of our investment philosophy is based on an unwavering commitment to investing in quality businesses. 

Jensen's Perspective

Quality is Location and Domicile Agnostic

Jensen believes that sustainable competitive advantages and persistent, strong business performance yield long-term growth and capital appreciation.

All data as of December 31, 2022. *For a representative account of the Jensen Global Quality Growth Equity Composite

Miscellaneous 79 final EXPLORE VEHICLES
25- 40
Portfolio Holdings
85 %
Active Share*
15 %
ROE Threshold
11
Countries Represented

How We Think

Insights
15 March 2023
Around the Bend: What to Tell Clients in Difficult Markets
How can advisers put the current market environment in perspective to help their clients prepare for whatever comes next?
Click here
false
News
9 March 2023
Press Release: Three New Equity Ownership Shareholders
We are pleased to welcome Alexandria Sorosky, MaryAnn Dahl and Todd Schoen as the most recent additions to firm ownership.
Click here
false
Insights
2 March 2023
Pfizer: Short-Term Noise or Long-Term Benefits?
Pfizer stands to lose approximately $17B in sales over the next several years due to the loss of exclusivity on several large drug franchises. Find out why we believe this short-term noise may not outweigh the benefits for long-term investors.
Click here
false
News
15 February 2023
Press Release: Promotions of Adam Dunn and Jeff Wilson
We are pleased to announce the promotion of Adam Dunn to Director of Trading and Jeff Wilson to Portfolio Manager.
Click here
false
Insights
13 February 2023
How Diageo Is Serving Up Higher Profits with a Focus on Premium Spirits
With its marketing and distribution muscle, Diageo (DEO) can get its products in stores and bars everywhere. They also have deep pockets to buy up artisanal brands that have already built a following.
Click here
false
Insights
31 January 2023
With Covid Stumbles Behind It, AstraZeneca’s Superior Pipeline Can Shine
AstraZeneca can weather periodic hiccups with a diverse portfolio of blockbuster drugs, including a COVID-19 vaccine.
Click here
true